Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

GLUTARALDEHYDE, a di-aldehyde fixative, has been found to bind antibodies rapidly and permanently to antigens of red blood cells ... 1 in which purified cold agglutinins (anti-I), labelled ...